This PDF is the current document as it appeared on Public Inspection on 12/20/2011 at 08:45 am.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) for zinc gluconate injectable solution from Technology Transfer, Inc., to Ark Sciences, Inc.
This rule is effective December 21, 2011.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, (240) 276-8300, email: email@example.com.End Further Info End Preamble Start Supplemental Information
Technology Transfer, Inc., 33 East Broadway, suite 190, Columbia, MO 65203 has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141-217 for NEUTERSOL (zinc gluconate) Injectable Solution to Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218. Accordingly, the Agency is amending the regulations in 21 CFR 522.2690 to reflect the transfer of ownership.
Following this change of sponsorship, Technology Transfer, Inc., is no longer the sponsor of an approved application. Accordingly, § 510.600 (21 CFR 510.600) is being amended to remove the entries for this firm.
In addition, Ark Sciences, Inc., is not currently listed in the animal drug regulations as a sponsor of an approved application. Accordingly, § 510.600 is being amended to add entries for this sponsor.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.Start List of Subjects
List of Subjects
- Administrative practice and procedure
- Animal drugs
- Reporting and recordkeeping requirements
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:Start Part
PART 510—NEW ANIMAL DRUGSEnd Part Start Amendment Part
1. The authority citation forEnd Amendment Part Start Amendment Part
2. In § 510.600, in the table in paragraph (c)(1), remove the entry for “Technology Transfer, Inc.”; alphabetically add a new entry for “Ark Sciences, Inc.”; and in the table in paragraph (c)(2), remove the entry for “067647”; and in numerical sequence add a new entry for “076175” to read as follows:End Amendment Part
(c) * * *
(1) * * *
|Firm name and address||Drug labeler code|
|* * * * *|
|Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218||076175|
|* * * * *|
(2) * * *
|Drug labeler code||Firm name and address|
|* * * * *|
|076175||Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218.|
|* * * * *|
PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGSEnd Part Start Amendment Part
3. The authority citation forEnd Amendment Part
4. In paragraph (b) of § 522.2690, remove “067647” and in its place add “076175”.End Amendment Part Start Signature
Dated: December 8, 2011.
Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.
[FR Doc. 2011-32591 Filed 12-20-11; 8:45 am]
BILLING CODE 4160-01-P